IP Library Granted Patent US 11,952,572
Granted Patent B2
US 11,952,572 · App. 16/639,424 · Granted Apr 9, 2024

Methods of treating cancer by inhibiting SETD2

Inventors: Alexandra Rose Grassian (Cambridge, MA); Michael Thomenius (Arlington, MA); Jennifer Anne Totman (Berlin, MA)
Assignee: Epizyme, Inc.
C12N15/1137A61K31/7076A61K31/7088A61K38/465A61K39/3955A61P35/00C07K16/40C12N5/0693C12N9/22C12N15/11C07K2317/76C12N2310/14C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,952,572
App. No.
16/639,424
Granted
Apr 9, 2024
Kind
B2
Abstract

The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancer, i.e., pancreatic cancer or esophageal cancer, by administering to a human subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.

Claims (1)

1. A method of reducing or inhibiting proliferation of a cancer cell, comprising (i) contacting a cancer cell with an effective amount of a Suppressor of variegation, Enhancer of zeste, and Trithorax domain containing 2 (SETD2) inhibitor, wherein the SETD2 inhibitor is N-propyl sinefungin or N-benzyl sinefungin; and (ii) reducing or inhibiting proliferation of said cancer cell, wherein said cancer cell is a pancreatic ductal carcinoma cell line or an esophageal cancer cell line OE21.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2024
From: GRASSIAN, ALEXANDRA ROSE; THOMENIUS, MICHAEL; TOTMAN, JENNIFER ANNE
To: EPIZYME, INC.
Reel/Frame 066585/0722 →
Cited By (1)
US 12,691,111